secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001171843-23-002866
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics Q1 net loss $7.8M; cash $175M funds operations into 2026
-----------------------------------------------------------------------------

- Net loss of $7.8M ($0.06 per share) vs $7.2M in Q1 2022; R&D spend up 50% to $6.6M on CTX-009.
- Cash and marketable securities $175M at March 31, 2023, providing runway into 2026.
- Phase 2/3 of CTX-009 in biliary tract cancers enrolling; top-line data expected H1 2024.
- Phase 2 CTX-009 in colorectal cancer initial data expected Q3 2023; ASCO GI data showed 37.5% ORR.
- Appointed Minori Rosales as SVP Head of Clinical Development and Richard Lindahl to board as Audit Chair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184323002866/0001171843-23-002866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184323002866/f8k_050323.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-002866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer